Research programme: cannabinoid based therapeutics - Therapix Biosciences

Drug Profile

Research programme: cannabinoid based therapeutics - Therapix Biosciences

Alternative Names: palmitoylethanolamide; palmitoylethanolamide combination therapies - Therapix; THX-ULD01

Latest Information Update: 12 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dekel Pharmaceuticals
  • Developer Therapix Biosciences
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cognition disorders
  • Research Inflammation; Pain

Most Recent Events

  • 10 Aug 2017 Therapix plans a phase I trial for Cognition disorders in patients with Traumatic brain injury
  • 05 Apr 2017 Therapix in-licenses nasal drug delivery technology from Yissum
  • 22 Mar 2017 Therapix plans a phase IIa trial for Cognition disorders in North America (Therapix Biosciences website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top